Keyphrases
Placebo-controlled
100%
Raynaud's Phenomenon
100%
Systemic Sclerosis
100%
Dose Comparison
100%
Iloprost
100%
Placebo
33%
End of Treatment
20%
Adverse Events
13%
Twice Daily
13%
Treatment Difference
13%
University Hospital
6%
Treatment Duration
6%
Intention-to-treat
6%
Optimal Dose
6%
Tolerability
6%
Patient Diaries
6%
Percentage Reduction
6%
Group Comparison
6%
Treatment Discontinuation
6%
Attack Severity
6%
Premature Discontinuation
6%
European Universities
6%
Total Daily Dose
6%
Physician Global Assessment
6%
Medicine and Dentistry
Placebo
100%
Systemic Scleroderma
100%
Iloprost
100%
Raynaud Phenomenon
100%
Drug Dose Comparison
100%
Adverse Event
13%
Prematurity
6%
Intention-to-Treat Analysis
6%
Side Effect
6%
Optimal Drug Dose
6%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Raynaud Phenomenon
100%
Systemic Sclerosis
100%
Iloprost
100%
Adverse Event
13%
Side Effect
6%
Prematurity
6%
Tolerability
6%
Immunology and Microbiology
Systemic Scleroderma
100%
Iloprost
100%
Raynaud Phenomenon
100%
Drug Dose Comparison
100%
Optimal Drug Dose
6%